Abstract

Alternative splicing (AS) is one of the key processes involved in the regulation of gene expression in eukaryotic cells. AS catalyzes the removal of intronic sequences and the joining of selected exons, thus ensuring the correct processing of the primary transcript into the mature mRNA. The combinatorial nature of AS allows a great expansion of the genome coding potential, as multiple splice-variants encoding for different proteins may arise from a single gene. Splicing is mediated by a large macromolecular complex, the spliceosome, whose activity needs a fine regulation exerted by cis-acting RNA sequence elements and trans-acting RNA binding proteins (RBP). The activity of both core spliceosomal components and accessory splicing factors is modulated by their reversible phosphorylation. The kinases and phosphatases involved in these posttranslational modifications significantly contribute to AS regulation and to its integration in the complex regulative network that controls gene expression in eukaryotic cells. Herein, we will review the major canonical and noncanonical splicing factor kinases and phosphatases, focusing on those whose activity has been implicated in the aberrant splicing events that characterize neoplastic transformation.

Highlights

  • In eukaryotic cells, the expression of each gene is finely tuned by a complex network of regulative processes affecting all steps of transcript maturation, from nuclear transcription to cytosolic export and utilization of the mRNA

  • The RNA-based technologies exploit antisense oligonucleotide masking specific sequence elements to splicing factors and/or the spliceosome [130], whereas chemical approaches make use of drugs that directly target the activity of spliceosomal components, as for examples spliceostatin A, which inhibits the SF3b subunit of the U2 snRNP, thereby modulating the alternative splicing (AS) of genes important for cell cycle control [131]

  • Considering the important control exerted by protein kinases on AS, modulation of their activity represents a potential approach for the development of new drugs targeting RNA splicing in cancer therapy

Read more

Summary

Introduction

The expression of each gene is finely tuned by a complex network of regulative processes affecting all steps of transcript maturation, from nuclear transcription to cytosolic export and utilization of the mRNA. A crucial step in this regulative network is represented by pre-mRNA splicing, the molecular process that mediates the removal of intronic sequences and the joining of exons. What makes splicing an outstanding player in controlling gene expression is its flexibility, which allows a remarkable increase of the coding potential of the genome through alternative selection of exons. The spliceosome mediates the recognition of the short consensus sequences surrounding the 5󸀠-(GU) and the 3󸀠-(AG) splice site and catalyzes the two transesterification reactions necessary for the removal of the intron and ligation of the selected exons (reviewed in [4]). International Journal of Cell Biology transcription rate, and posttranslational modifications of both spliceosome components and auxiliary splicing factors, among which reversible phosphorylation acts as a major player

Impact of Phosphorylation on the Catalysis of Splicing
Phosphorylation and Splicing Factors
Splicing Factor Kinases
SR-Protein Specific Kinases
Signaling-Activated Splicing Factor Kinases
Other Kinases
Splicing Factor Kinases in Cancer and Other Human Diseases
Protein Phosphatase Regulating Splicing Factors
Findings
10. Concluding Remarks
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call